Evicenter
MarkdownMedical informationP&T meetings
Lysergide (DT120)

Generalized anxiety disorder

Also known as MM120
Launch
Not announced
Last updated
199 sources

Section 3 of 6

Product information and disease description

379 evidence topics · 173 sources

Product description

Phase of product development

Launch

No evidence found.

Investigational status and current development phase
Controlled substance scheduling: rescheduling by the DEA and states required after approval
Executive Order 14401 of April 2026: priority vouchers and timely rescheduling of psychedelic drugs

Product information

Generic, brand name and therapeutic class of product
Dosage forms and strengths
Commercial dosage form, strengths, and package configuration

No evidence found.

Average sales price and wholesale acquisition cost

Not applicable.

American hospital formulary service (AHFS), or other drug classification
AHFS Pharmacologic-Therapeutic Classification and Anatomical Therapeutic Chemical code

No evidence found.

Indication
Proposed labeled indication submitted to a regulator

No evidence found.

Pharmacology
Mechanism of action
Pharmacodynamics
Thorough QT study of DT120 ODT: treatment-emergent adverse events
MeasurePhase 1 TQT study, DT120 ODT (n = 58)
Any TEAE“57 (98.3)”
TEAE leading to treatment withdrawal“0”
Mild“27 (46.6)”
Moderate“27 (46.6)”
Severe“3 (5.2)”
Any related TEAE“57 (98.3)”
Dose-response of subjective effects and ceiling at 100 µg in healthy participants
Pharmacokinetics
Food effect study of DT120 ODT: treatment-emergent adverse events by cohort
MeasureDT120 ODT + high-fat meal (n = 31)DT120 ODT + low-fat meal (n = 28)
Any TEAE“31 (100.0)”“28 (100.0)”
TEAE leading to treatment withdrawal“1 (3.2)”“2 (7.1)”
Mild“24 (77.4)”“22 (78.6)”
Moderate“7 (22.6)”“5 (17.9)”
Severe“0”“1 (3.6)”
Any related TEAE“31 (100.0)”“28 (100.0)”
Absorption, peak concentration, and half-life of oral LSD
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions

Not applicable.

Special populations
Drug/Drug, drug/disease interactions
Effects of other drugs on Lysergide
Paroxetine (selective serotonin reuptake inhibitor and strong CYP2D6 inhibitor)
Effects of Lysergide on other drugs
Dosing and administration
Dosage
Dose selection from the phase 2b dose-finding trial
Administration
Phase 2b dosing session procedures and 12-hour monitoring

“On the dosing day, participants received a single oral dose of MM120 or placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Each participant was continuously monitored on-site for safety and comfort by the same 2 dosing session monitors who conducted the participant’s educational session during the baseline visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Participant dosing sessions were conducted individually in a private aesthetically pleasant room.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Participants were offered standardized music and eyeshades and they could lie down, move freely around the room, read, write, or draw.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Vital signs were measured throughout the dosing session and a physician was on-site in case comfort medications were needed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Starting 8 hours after the dose, participants were assessed hourly to characterize the resolution of the drug effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Continuous monitoring was required for a minimum of 12 hours.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Access and distribution
Distribution channel and specialty pharmacy arrangements

No evidence found.

Co-prescribed/Concomitant therapies
Effect of Lysergide on quality measures
Lysergide-specific effect on quality measures

No evidence found.

Product comparison
FDA-approved pharmacotherapies for GAD in adults

“Escitalopram has been approved by the FDA for the treatment of GAD in adults” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“As an FDA-approved treatment for GAD in adults, immediate release paroxetine has been studied extensively and multiple studies support its efficacy in adults with GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In adults with GAD, venlafaxine (75–225 mg/day) effectively reduces anxiety symptoms [36–38] and was the first FDA-approved antidepressant for the treatment of GAD in this age group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Duloxetine, a selective 5-HT and norepinephrine reuptake inhibitor, is FDA-approved for the treatment of GAD, MDD, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Buspirone, a non-benzodiazepine anxiolytic and 5-HT1A receptor agonist, is approved for the treatment of GAD in adults” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“As such, alprazolam is the only benzodiazepine to be formally approved by the FDA for the treatment of GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Prescriber intent to administer DT120 compared with esketamine: company market research
Response of high-priority GAD prescribersDT120 ODTEsketamine
Prescribe and administer the treatment in own practice“51%”“26%”
Refer out (for DT120, the treatment; for esketamine, for esketamine)“40%”“61%”
Only discuss if a patient raises it (DT120), or refer out for evaluation without specifying esketamine“9%”“14%”
Other psychedelic and serotonergic agents in development for GAD and depressive disorders, as listed by the company

“A number of companies are developing product candidates with similar mechanisms to DT120 that are intended for the treatment of anxiety and depressive disorders, including AtaiBeckley Inc. (“AtaiBeckley”), Compass Pathways plc (“Compass”), GH Research (“GH Research”), Cybin, Inc. doing business as Helus Pharma (“Helus”), Johnson & Johnson (“J&J”), Otsuka Pharmaceutical Co. Ltd. (“Otsuka”) and others.” (opens the source at this quote in a new tab)

“Helus is currently evaluating HLP004 (a serotonin receptor agonist) in a Phase 2 trial for the treatment of GAD, with an anticipated topline data readout in the first quarter of 2026. In addition, Otsuka is currently conducting a Phase 2/3 clinical trial of ulotaront (SEP-363856), a trace amine-associated receptor 1 (TAAR1) agonist with 5-HT1A agonist activity, for the treatment of GAD and MDD.” (opens the source at this quote in a new tab)

“Intra-Cellular Therapies, now a part of J&J (“Intra-Cellular”), is currently developing multiple product candidates that are in various phases of development for the treatment of GAD and MDD, including CAPLYTA (lumateperone), which was approved by the FDA in November 2025 as an adjunctive treatment for adults with MDD, and ITI-1284 ODT-SL for GAD.” (opens the source at this quote in a new tab)

“Compass is developing COMP360 (a proprietary formulation of psilocybin) that is in Phase 3 clinical trials for the treatment of TRD in adults and is being studied in other psychiatric indications (anorexia nervosa and post-traumatic stress disorder).” (opens the source at this quote in a new tab)

“There are also many other public and private companies developing therapeutics from the psychedelic drug class at various stages of development, including certain short-acting psychedelic drugs.” (opens the source at this quote in a new tab)

Head-to-head clinical comparison of DT120 with an approved GAD treatment

No evidence found.

Place of product in therapy

Disease description

Definition and etiology
Heritability: family and twin studies
Environmental risk factors: adverse life events and parenting
Epidemiology
Incidence of Generalized anxiety disorder
Age at onset: meta-analysis of 192 epidemiological studies
MeasureGeneralised anxiety disorder
No of samples“24”View highlighted excerpt for this quote
Peak age at onset (years)“15.5”View highlighted excerpt for this quote
Proportion onset by 14 years“8.6%”View highlighted excerpt for this quote
Proportion onset by 18 years“20.4%”View highlighted excerpt for this quote
Proportion onset by 25 years“33.0%”View highlighted excerpt for this quote
25th percentile age at onset (years)“20”View highlighted excerpt for this quote
Median age at onset (years)“32”View highlighted excerpt for this quote
75th percentile age at onset (years)“42”View highlighted excerpt for this quote
High-income North America incidence of anxiety disorders (all types combined): Global Burden of Disease Study 2019
RegionIncident cases in 2019, millions (95% UI)Age-standardised incidence rate per 1000 in 2019 (95% UI)
High-income North America“2.86 (2.31, 3.52)”View highlighted excerpt for this quote“8.06 (6.44, 9.87)”View highlighted excerpt for this quote
Prevalence of Generalized anxiety disorder
United States past-year prevalence by clinical interview: MDPS, adults aged 18 to 65, 2020 to 2022
United States prevalence of DSM-5 generalized anxiety disorder: World Mental Health Surveys, US survey (n=9282)
Natural history, survival, and mortality
Recovery and recurrence over 12 years: Harvard/Brown Anxiety Disorders Research Program
Mortality: Danish total-population cohort
Pathophysiology
Threat-response circuitry: anxiety disorders

“This research suggests that perturbed threat responding in anxiety disorders involves dysfunction in the circuitry that supports core psychological processes, such as attention, emotion, learning, and memory.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Many brain imaging studies have examined the structure of regions that basic neuroscience implicates in threat responding, showing structural alterations in anxiety disorders within medial temporal, prefrontal cortex, and cingulate regions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“With functional MRI, patients who are anxious have an altered response in temporal and prefrontal brain regions, which has also been shown in functional MRI research regarding attention.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“When people are exposed to stressors, such as public speaking, scary pictures, or painful stimulation, studies generally report increased stress responses in people with anxiety disorders versus controls across many measures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“For peripheral measures, rarely do effect sizes exceed a Cohen’s d of 0·50, indicating that these are not useful biomarkers that currently guide diagnosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Diagnosis
Exclusion of medical causes and differential diagnosis
Accuracy of the GAD-7 and GAD-2 screening instruments
Clinical presentation - signs and symptoms
Functional impairment: social, occupational, and role functioning
Long-term morbidity
Comorbidity and the course of anxiety disorders
Burden of Generalized anxiety disorder
Humanistic burden and health-related quality of life
Economic burden and healthcare resource utilization
Healthcare resource use, unadjusted, and payer survey: 2022 US National Health and Wellness Survey, sponsor-funded
U.S. health care spending on anxiety disorders, 2016
MeasureAnxiety disorders
Spending rank among 154 health conditions“21”View highlighted excerpt for this quote
Health care spending, 2016 $Billion (95% CI)“42.4 (37.8-47.7)”View highlighted excerpt for this quote
Age 20 to 64 years, % of spending“75.3”View highlighted excerpt for this quote
Public insurance, % of spending“49.6”View highlighted excerpt for this quote
Private insurance, % of spending“41.2”View highlighted excerpt for this quote
Out-of-pocket payments, % of spending“9.2”View highlighted excerpt for this quote
Ambulatory care, % of spending“55.7”View highlighted excerpt for this quote
Inpatient care, % of spending“7.0”View highlighted excerpt for this quote
Prescribed pharmaceuticals, % of spending“21.3”View highlighted excerpt for this quote
Economic impact of Generalized anxiety disorder on families

Not applicable.

Economic impact of diagnostic testing

Not applicable.

Approaches to treatment

Current treatment options and standard of care
Psychological therapies
CANMAT guideline: efficacy of CBT and other psychological treatments
Meta-analysis of psychotherapy and medication trials: 79 randomized trials

“Seventy-nine randomized controlled trials (RCT) including 11,002 participants with a diagnosis of GAD were included in a meta-analysis that tested the efficacy of psychotherapies or medications for GAD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Consistent with prediction, evidence-based psychotherapies outperformed control conditions on primary outcome measures at posttreatment with a medium to large effect size (g = 0.76, 95% CI: 0.61–0.91, p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Within psychotherapy comparisons, pill placebo-controlled studies had the highest effect size (n = 3, g = 1.44, 95% CI: 0.94–1.94, p < 0.001), followed by WL controls (n = 22, g = 0.90, 95% CI: 0.73–1.08, p < 0.001), psychological placebo (n = 10, g = 0.47, 95% CI: 0.25–0.69, p < 0.001), and TAU (n = 5, g = 0.38, 95% CI: 0.05–0.71, p < 0.05;” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“There was evidence of publication bias in psychotherapy studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Because medication studies had more placebo control conditions than inactive conditions compared to psychotherapy studies, effect sizes between the domains should not be compared directly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Selective serotonin reuptake inhibitors
Adverse reactions with escitalopram in adult GAD trials: incidence table
Adverse reactionLexapro (N=429)Placebo (N=427)
Headache“24%”“17%”
Nausea“18%”“8%”
Ejaculation disorder“14%”“2%”
Somnolence“13%”“7%”
Insomnia“12%”“6%”
Dry mouth“9%”“5%”
Fatigue“8%”“2%”
Libido decreased“7%”“2%”
Anorgasmia“6%”“<1%”
Relapse after discontinuation: meta-analysis of relapse prevention trials, SSRI subgroup
Serotonin-Norepinephrine reuptake inhibitors
Venlafaxine extended-release: HAM-A results of the four adult GAD studies
Study and treatment groupLS mean change from baseline (SE)Placebo-subtracted difference (95% CI)
Study 1, venlafaxine XR 75 mg“-11.1 (0.95)”“-1.5 (-3.8, 0.8)”
Study 1, venlafaxine XR 150 mg“-11.7 (0.87)”“-2.2 (-4.5, 0.1)”
Study 1, venlafaxine XR 225 mg“-12.1 (0.81)”“-2.6 (-4.9, -0.3)”
Study 1, placebo“-9.5 (0.85)”
Study 2, venlafaxine XR 75 mg“-10.6 (0.82)”“-2.6 (-4.6, -0.5)”
Study 2, venlafaxine XR 150 mg“-9.8 (0.86)”“-1.7 (-3.8, 0.3)”
Study 2, placebo“-8.0 (0.73)”
Study 3, venlafaxine XR 37.5 mg“-13.8”“-2.8 (-5.1, -0.6)”
Study 3, venlafaxine XR 75 mg“-15.5”“-4.6 (-6.9, -2.3)”
Study 3, venlafaxine XR 150 mg“-16.4”“-5.5 (-7.8, -3.1)”
Study 3, placebo“-11.0”
Study 4, venlafaxine XR 75-225 mg“-13.4 (0.79)”“- 4.7 (-6.6, -2.9)”
Study 4, placebo“-8.7 (0.70)”
FDA-approved GAD indication: duloxetine

“Generalized anxiety disorder in adults and pediatric patients 7 years of age and older” (opens the source at this quote in a new tab)

“For most adults less than 65 years of age with GAD, initiate CYMBALTA 60 mg once daily. For some patients, it may be desirable to start at 30 mg once daily for 1 week, to allow patients to adjust to CYMBALTA before increasing to 60 mg once daily. While a 120 mg once daily dosage was shown to be effective, there is no evidence that doses greater than 60 mg/day confer additional benefit.” (opens the source at this quote in a new tab)

“The efficacy of CYMBALTA in the treatment of generalized anxiety disorder (GAD) was established in 1 fixed-dose randomized, double-blind, placebo-controlled trial and 2 flexible-dose randomized, double-blind, placebo-controlled trials in adult outpatients between 18 and 83 years of age meeting the DSM-IV criteria for GAD (Studies GAD-1, GAD-2, and GAD-3, respectively).” (opens the source at this quote in a new tab)

“In all 3 trials, CYMBALTA demonstrated superiority over placebo as measured by greater improvement in the Hamilton Anxiety Scale (HAM-A) total score (see Table 8) and by the Sheehan Disability Scale (SDS) global functional impairment score.” (opens the source at this quote in a new tab)

“Patients treated with CYMBALTA (N=151) demonstrated significantly greater improvement compared with placebo (N=140) on mean change from baseline to endpoint as measured by the HAM-A total score (see Table 8).” (opens the source at this quote in a new tab)

Adverse reactions and discontinuation with venlafaxine extended-release

“The most commonly observed adverse reactions in the clinical study database in Effexor XR treated patients in MDD, GAD, SAD, and PD (incidence ≥5% and at least twice the rate of placebo) were: nausea (30.0%), somnolence (15.3%), dry mouth (14.8%), sweating (11.4%), abnormal ejaculation (9.9%), anorexia (9.8%), constipation (9.3%), impotence (5.3%), and decreased libido (5.1%).” (opens the source at this quote in a new tab)

“Combined across short-term, placebo-controlled premarketing studies for all indications, 12% of the 3,558 patients who received Effexor XR (37.5-225 mg) discontinued treatment due to an adverse experience, compared with 4% of the 2,197 placebo-treated patients in those studies.” (opens the source at this quote in a new tab)

“In controlled trials, there were dose-related increases in systolic and diastolic blood pressure, as well as cases of sustained hypertension” (opens the source at this quote in a new tab)

“Monitor blood pressure before initiating treatment with Effexor XR and regularly during treatment.” (opens the source at this quote in a new tab)

“Abrupt discontinuation or dose reduction of venlafaxine at various doses has been found to be associated with the appearance of new symptoms, the frequency of which increased with increased dose level and with longer duration of treatment.” (opens the source at this quote in a new tab)

Adverse reactions and discontinuation with duloxetine

“Approximately 13.7% (139/1018) of the CYMBALTA-treated patients in placebo-controlled adult trials for GAD discontinued treatment due to an adverse reaction, compared with 5% (38/767) for placebo-treated patients.” (opens the source at this quote in a new tab)

“Common adverse reactions reported as a reason for discontinuation and considered to be drug-related (as defined above) included nausea (CYMBALTA 3.3%, placebo 0.4%), and dizziness (CYMBALTA 1.3%, placebo 0.4%).” (opens the source at this quote in a new tab)

“The most commonly observed adverse reactions in CYMBALTA-treated patients in all the pooled adult populations (i.e., MDD, GAD, DPNP, FM, OA, and CLBP) (incidence of at least 5% and at least twice the incidence in placebo-treated patients) were nausea, dry mouth, somnolence, constipation, decreased appetite, and hyperhidrosis.” (opens the source at this quote in a new tab)

“There have been reports of hepatic failure, sometimes fatal, in patients treated with CYMBALTA.” (opens the source at this quote in a new tab)

“Following abrupt or tapered discontinuation in adult placebo-controlled clinical trials, the following symptoms occurred at 1% or greater and at a significantly higher rate in CYMBALTA-treated patients compared to those discontinuing from placebo: dizziness, headache, nausea, diarrhea, paresthesia, irritability, vomiting, insomnia, anxiety, hyperhidrosis, and fatigue.” (opens the source at this quote in a new tab)

Relapse after discontinuation: meta-analysis of relapse prevention trials, SNRI subgroup
SubgroupNumber of studiesOdds ratio of relapse, placebo relative to continued antidepressant (95% CI)
SNRI“3”View highlighted excerpt for this quote“5.03 (1.31 to 19.40)”View highlighted excerpt for this quote
Pregabalin
Buspirone
Benzodiazepines
Hydroxyzine
Second-generation antipsychotics
Other antidepressants
CANMAT guideline: agomelatine, imipramine, bupropion XL, vortioxetine, mirtazapine, and trazodone
Limitations of current therapies
Summary

Up to 50% of patients with GAD have an inadequate response to available agents, and 50 to 67% respond adequately to a first treatment trial. Reported response and remission rates are 60% to 68% and 30% to 36% with SSRIs and 56% to 58% and 31% to 38% with SNRIs; another review gives SSRI response in randomized trials as 60% to 75% against 40% to 60% with placebo. One source advises telling patients that treatment periods of up to 12 weeks may be needed to assess efficacy. SSRI and SNRI discontinuation rates are 20% to 23%, associated with nausea, sexual dysfunction, and slow onset. Across 28 anxiety disorder studies (n=5233), relapse prevalence was 36.4% in placebo groups and 16.4% in antidepressant groups; in 6 GAD studies, the odds ratio for relapse after discontinuation was 4.20 (95% CI 2.42 to 7.28). Benzodiazepines carry a class boxed warning for abuse, addiction, physical dependence, and withdrawal; pregabalin is a Schedule V controlled substance; buspirone efficacy beyond 3 to 4 weeks has not been demonstrated in controlled trials. The prescribing information of escitalopram, paroxetine, venlafaxine extended-release, duloxetine, and alprazolam lists GAD among their indications. The indication lists in the prescribing information of pregabalin, a recommended first-line therapy in one source, and of quetiapine extended-release, a second-line choice in the same source, do not include GAD.

Relapse after antidepressant discontinuation
SubgroupStudiesOdds ratio for relapse after discontinuation (95% CI)
Generalised anxiety disorder (DSM-IV)“6”View highlighted excerpt for this quote“4.20 (2.42 to 7.28)”View highlighted excerpt for this quote
Place in treatment, anticipated use, and care setting
Summary: anticipated population and place in treatment

Lysergide (DT120 ODT) is investigational; the sponsor anticipates an NDA filing in the first half of 2027, states that its clinical trials are currently the appropriate way to receive the drug, and is evaluating when expanded access may be made available. The sponsor's 2026 corporate presentation counts 4.2 million U.S. adults with GAD or MDD failed by two or more prescription treatments, of 13 million treated with prescription drugs. In the Voyage trial, 78 of 214 participants (36%) had two or more past GAD medications, 65 (30%) had one, and 71 (33%) had none. The sponsor reports that payers expect to manage use with prior authorization in line with other branded psychiatric products. The NICE guideline places complex treatment-refractory GAD at step 4, managed with specialist care such as complex drug or psychological regimens and multi-agency input. One author names, as conditions for adoption, full peer-reviewed reporting of the Voyage and Panorama topline results, formulation bridging, durability and retreatment data, management of functional unblinding, and a scalable model of monitored care.

Summary: care setting, monitoring, and scheduling

The studied paradigm is a single dosing visit with no psychotherapy, continuous monitoring by dosing session monitors, an end of session when checklist criteria are met, and follow-up visits for assessment only. The Phase 3 trials required 8 hours of monitoring; average time to checklist clearance was 5.8 to 6.4 hours across Emerge, Voyage, and Panorama (Part A), and normal activities, including driving, resume the next day. The sponsor proposes 5 to 8 hours of monitoring through the checklist, which it intends to reflect requirements under a potential REMS. It plans delivery through certified third-party treatment sites, citing ~4,000 interventional psychiatry clinics (about half of the estimated Spravato REMS sites), and is engaged with the VA. Lysergide is a Schedule I substance: after FDA approval, the DEA and states must reschedule the product before it can be marketed, state scheduling may delay sale, and the active ingredient would remain subject to manufacturing quotas.

Treatment history of participants in the Voyage trial
Number of past GAD medicationsDT120 ODT (n = 107)Placebo ODT (n = 107)Overall (N = 214)
None“35 (33)”“36 (34)”“71 (33)”
One“31 (29)”“34 (32)”“65 (30)”
Two or more“41 (38)”“37 (35)”“78 (36)”
Heterogeneity of treatment effect
DT120 in Voyage: change in HAM-A score at Week 12 by subgroup
SubgroupPlacebo-adjusted LS mean change (SE)
All participants“−5.4 (1.0)”
Time since GAD symptoms began, less than 22 years (n = 107)“−5.9 (1.4)”
Time since GAD symptoms began, 22 years or more (n = 107)“−4.7 (1.5)”
Previous GAD medications, fewer than 2 (n = 136)“−4.2 (1.2)”
Previous GAD medications, 2 or more (n = 78)“−5.6 (1.7)”
Male (n = 77)“−7.1 (1.7)”
Female (n = 137)“−5.5 (1.2)”
Care management intervention strategies
Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.

Expected outcomes of therapy
Summary: symptom change, response, and remission

In the phase 3 trials, which compared a single dose of DT120 ODT 100 µg with placebo and have reported company topline results, the LS mean HAM-A total score decreased by 11.6 points (Voyage) and 9.8 points (Panorama) at Week 12, compared with 6.2 and 4.7 points with placebo. The placebo-adjusted differences of 5.4 and 5.1 points compare with a minimal clinically important difference of 2.5 points used in the phase 2b trial. At Week 12, 43% (Voyage) and 32% (Panorama) of participants given DT120 had a response (HAM-A improvement of 50% or more) and 14% and 15% a remission (HAM-A of 7 or less), compared with 16% and 14% (response) and 4% and 4% (remission) with placebo. In the phase 2b trial, which used capsules, response at Week 12 occurred in 26 of 40 participants (65.0%) given 100 µg and 12 of 39 (30.8%) given placebo, and remission in 19 (47.5%) and 8 (20.5%).

Summary: onset, durability, and the dosing session

Differences from placebo were present early: CGI-S change at Day 2 differed by -0.8 in both phase 3 trials, and HAM-A change at Week 1 by -7.7 (Voyage) and -5.3 (Panorama) points. The controlled comparison covers 12 weeks after one dose. In the 40-week extensions participants could receive open-label DT120 ODT (in Voyage, up to four additional doses based on symptom severity); in interim analyses of partial data (cutoffs July 15, 2026 and August 11, 2026), 60% of 37 Voyage participants and 48% of 27 Panorama participants given DT120 in Part A had a HAM-A response at Week 28. FDA guidance asks sponsors to follow participants beyond Week 12 for symptom recurrence or a need for repeat dosing. Transient perceptual, affective, and emotional effects occurred primarily on the dosing day. Participants were observed by dosing session monitors for at least 8 hours and until they cleared an end-of-session checklist; mean time to clearance was 6.4 hours in Voyage and 6.2 hours in Panorama, and by hour 8, 92% (topline announcement) or 90% (poster) of Voyage participants, 94% of Panorama participants, and 97% across more than 1,000 phase 3 sessions through September 10, 2026 had cleared it. The sponsor states that normal activities, including driving, resume the next day.

DT120 in Voyage: response and remission at Week 12
Outcome at Week 12DT120 ODTPlacebo ODTPlacebo-adjusted difference
HAM-A response rate (≥50%)“43%”“16%”“27% (p<0.0001)”
HAM-A remission rate (≤7)“14%”“4%”“10% (p=0.0222)”
DT120 in Panorama: response and remission at Week 12
Outcome at Week 12DT120 ODT 100 µgPlacebo ODTPlacebo-adjusted difference
HAM-A response rate (≥50%)“32%”“14%”“18% (p<0.05)”
HAM-A remission rate (≤7)“15%”“4%”“12% (p<0.05)”